OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing

May 16th, 2022 18:14 EST

london may 16 2022 globe newswire okyo pharma limited nasdaq okyo lse okyo “okyo pharma” or the “company“ a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain announced the pricing of an underwritten public offering of 625 000 american depositary shares the “adss” at a public offering price of $4 00 per ads in addition okyo pharma has granted the underwriters a 45 day option to purchase up to an additional 93 750 adss to cover over allotments if any the gross proceeds to the company from this offering are expected to be approximately $2 500 000 before deducting underwriting discounts commissions and other offering expenses and excluding the exercise of the over allotment option if any the offering is expected to close on may 19 2022 subject to customary closing conditions the company has received approval to list its adss on the nasdaq capital market under the symbol “okyo” and the adss are expected to begin trading on may 17 2022 okyo pharma intends to use the net proceeds of the offering to advance ok 101 to the filing of an ind to treat ded to fund the initial phase 2 clinical trial of ok 101 in ded patients and the remaining proceeds for working capital and other general corporate purposes thinkequity is acting as the sole book running manager for the offering the registration statement on form f 1 file no 333 263326 relating to the shares being sold in this offering has been filed with the u s securities and exchange commission the “sec” and became effective on may 16 2022 a final prospectus related to the proposed offering will be filed and made available on the sec’s website at https www sec gov the offering is being made only by means of a prospectus electronic copies of the final prospectus may be obtained when available from thinkequity 17 state street 22nd floor new york new york 10004 by telephone at 877 436 3673 and by email at [email protected] equity com this press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction about okyo pharma limitedokyo pharma limited nasdaq okyo lse okyo is a biotechnology company developing next generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain okyo’s research program is focused on a novel g protein coupled receptor or gpcr which okyo believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need okyo’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions the company is presently developing ok 101 its lead preclinical product candidate for the treatment of dry eye disease “ded” the company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain uveitis and allergic conjunctivitis forward looking statementscertain statements made in this announcement are forward looking statements including with respect to the creation of a trading market for adss representing the ordinary shares in the united states these forward looking statements are not historical facts but rather are based on the company s current expectations estimates and projections about its industry its beliefs and assumptions words such as anticipates expects intends plans believes seeks estimates and similar expressions are intended to identify forward looking statements these statements are not guarantees of future performance and are subject to known and unknown risks uncertainties and other factors some of which are beyond the company s control are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements including market conditions whether the proposed offering is completed and the satisfaction of customary closing conditions related to the proposed offering the company cautions security holders and prospective security holders not to place undue reliance on these forward looking statements which reflect the view of the company only as of the date of this announcement the forward looking statements made in this announcement relate only to events as of the date on which the statements are made the company will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority investor relations contact redchip companies inc investor relations dave gentry +1 407 491 4498


You must be logged in to post a comment.

Related Recent Publications

You must be logged in to post a comment.

Email newsletter

Receive the latest stock news and signals